Omiganan

Summary

Omiganan (CHEMBL1615933) is a phase-3 clinical-stage protein; indicated across 7 conditions including rosacea and atopic eczema.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 7 conditions
• Clinical trials: 10
• Chemistry: 1779.1 Da · C90H127N27O12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1615933
Name	Omiganan
Type	Protein
Max phase	3
FDA approved	no
PubChem CID	16131445
Molecular formula	C90H127N27O12
Molecular weight	1779.1
InChIKey	MVPAMLBUDIFYGK-BHDRXCTLSA-N

SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CC6=CNC7=CC=CC=C76)C(=O)N8CCC[C@H]8C(=O)N[C@@H](CC9=CNC1=CC=CC=C19)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N)N

IUPAC name: (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide

Also known as: Omiganan, OMIGANAN

Parent form; salt/anhydrous children: CHEMBL1793889

Patent coverage: 100 distinct patent families (233 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rosacea	3	MONDO:0006604	EFO:1000760
atopic eczema	2	MONDO:0004980	EFO:0000274
vulvar intraepithelial neoplasia	2	MONDO:0005198	EFO:0002627
acne	2	MONDO:0011438	EFO:0003894
anogenital human papillomavirus infection	2	MONDO:0005647	EFO:0007147
seborrheic dermatitis	2	MONDO:0006608	EFO:1000764

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00231153	PHASE3	COMPLETED	Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters
NCT00608959	PHASE3	COMPLETED	Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects
NCT02576847	PHASE3	COMPLETED	Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
NCT01784133	PHASE2	COMPLETED	A Twelve Week Safety and Efficacy Study in Rosacea
NCT02571998	PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris
NCT02596074	PHASE2	COMPLETED	Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN
NCT02849262	PHASE2	COMPLETED	Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts
NCT03091426	PHASE2	COMPLETED	Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis
NCT03688971	PHASE2	UNKNOWN	Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
NCT03071679	PHASE1	COMPLETED	Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).